It's been more than three years since Amgen's multiple myeloma treatment Kyprolis won approval from U.S. regulators. Now, it's finally done the same in Europe--and with competition heating up across the pond, the go-ahead couldn't have come at a better time for the California biotech.
As the number of people living with cancer increases, pharma is rethinking how it treats those patients--both with drugs and services. And as AstraZeneca beefs up its oncology portfolio with a couple of lung cancer meds, it's developing services designed to help those cancer patients in day-to-day life, akin to outreach for patients with chronic diseases. Read more >>
October's top 10 biggest spenders on pharma TV advertising dropped just over $110 million to promote prescription drugs last month. That compares with $92.2 million spent by the top 10 in September, an increase of about 20% month over month, according to data from real-time TV tracker iSpot.tv, which custom crunches the monthly pharma numbers for FiercePharmaMarketing. Read more >>
In the wake of the American Medical Association's pan of DTC advertising last week, Kantar Media recently found that not all physicians dislike all advertising.
Meda Pharmaceutical's "Medikidz Explains Asthma" comic book series tells the story of asthma using precise clinical terms, but in a way that kids can understand and relate to.
Good-bye appointment TV, hello TV everywhere. As TV and video watching becomes wherever and whenever consumers want, marketers, including pharma, have had to shift strategies to reach those hard-to-pin-down viewers.
AstraZeneca scored a victory earlier this month after a Delaware district court ruled that Nexium's distinctive purple hue protects it from copycat competitors. Now Dr. Reddy's is claiming that AstraZeneca not only knew about but also allowed sales of its purple Nexium generics before filing its recent suit, breaking the terms of a previous settlement between the two companies.
Turing Pharmaceuticals has been saying for a while now that it would lower the price of its toxoplasmosis med, Daraprim, responding to growing backlash from lawmakers and the public after it bought the drug in August and jacked up its price by more than 5,000%. Now the company is taking a different route, opting to negotiate discounts with hospitals rather than cut the drug's list price.
Two healthcare agencies made a noteworthy list this week. And while it was only two, it still points to how pharma marketing is moving more mainstream as healthcare and prescription drugs infiltrate the daily political and cultural conversation.